RELAX
Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (RELAX)
Studienleiter | Prof. Dr. Christoph Röllig |
---|---|
EudraCT-Nr. | 2018-003025-28 |
Studientyp | Phase I / II |
Indikation | AML |
ClinicalTrial | NCT04330820 |